ST. PAUL, Minn.--(BUSINESS WIRE)--The European Medicines Agency (EMA) has granted approval for ProStrakan
Group plc to market SANCUSO® (Granisetron Transdermal System) in the
European Union (EU), with 3M
Drug Delivery Systems acting as the manufacturer. ProStrakan begins
marketing the product this month in the United Kingdom, Germany and the
Netherlands. Additional European countries are expected to be added in
Initially introduced in the United States in 2008, SANCUSO is the first
and only treatment for chemotherapy-induced nausea and vomiting that
does not require pills or intravenous (IV) administration. The
transdermal patch is applied to the upper arm and can be worn for seven
days, providing continuous transdermal delivery and eliminating the need
to take pills daily to control nausea and vomiting. This simple-to-use
treatment has been proven effective in patients at risk for
chemotherapy-induced nausea and vomiting.
“SANCUSO is a great illustration of the patient-friendly benefits of
transdermal treatment,” said Jim Ingebrand, president and general
manager, 3M Drug Delivery Systems. “We look forward to a continued
partnership with ProStrakan to bring SANCUSO to new markets.”
3M Drug Delivery Systems is applying more than 30 years of transdermal
experience and regulatory expertise to its manufacturing
responsibilities for SANCUSO. The company’s cGMP compliant manufacturing
and strength in global supply chain management ensure reliability and a
smooth process from start to finish for manufacturing partners.
“SANCUSO is already proving to be an important option for patients in
the U.S. suffering from chemotherapy-induced nausea and vomiting,” said
Jamie Blackport, senior vice president of international marketing at
ProStrakan. “We are excited about working together with 3M to bring this
important treatment to patients in the EU.”
While ProStrakan has previously relied on a different manufacturer for
the U.S. supply of SANCUSO, FDA approval is currently pending for the 3M
Drug Delivery Systems manufactured product.
About SANCUSO® (Granisetron Transdermal System)
SANCUSO® (Granisetron Transdermal System) is the first and only 5-HT3
receptor antagonist available as a transdermal patch for the prevention
of CINV. SANCUSO transdermal patch is indicated in adults for the
prevention of nausea and vomiting associated with moderately or highly
emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive
days, where oral anti-emetic administration is complicated by factors
making swallowing difficult.
ProStrakan Group plc is a rapidly growing specialty pharmaceutical
company engaged in the development and commercialization of prescription
medicines for the treatment of unmet therapeutic needs in major markets.
ProStrakan is a subsidiary of Kyowa Hakko Kirin Co. Ltd., the
Japan-based global specialty pharmaceutical company. ProStrakan's head
office is located in Galashiels in Scotland. The company’s development
capabilities are centred in Galashiels and Bridgewater, New Jersey, USA.
Sales and marketing of ProStrakan's portfolio of products are handled by
commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and
other EU countries. You can learn more about the business at: www.prostrakan.com
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech
companies to develop and manufacture pharmaceutical products using 3M's
inhalation, transdermal or microneedle drug delivery technology. 3M
offers a full range of feasibility, development and manufacturing
capabilities to help bring products to market. Regulatory expertise,
quality assurance, operations, marketed product support and other
in-house resources are available for each step of the development and
commercialization process. For more information, please visit www.3M.com/dds
or call 1-800-643-8086.
3M captures the spark of new ideas and transforms them into thousands of
ingenious products. Our culture of creative collaboration inspires a
never-ending stream of powerful technologies that make life better. 3M
is the innovation company that never stops inventing. With $30 billion
in sales, 3M employs about 88,000 people worldwide and has operations in
more than 70 countries. For more information, visit www.3M.com
or follow @3MNews on Twitter.
3M is a trademark of 3M Company.